GlobeNewsWire
12 Jun 2026, 10:46 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Culper Research alleges ADMA Biologics engaged in channel stuffing to report 20% revenue growth in 2025 when real growth was actually -3%. — Claims of systemic revenue manipulation and fake growth are severe catalysts for a stock collapse and loss of investor trust.
-0.90A securities fraud class action lawsuit has been filed against ADMA Biologics and its senior executives following a significant stock price drop. — Legal action for securities fraud introduces significant litigation risk and potential financial liabilities for the company.
-0.60Cantor downgraded ADMA Biologics' stock rating due to concerns raised by the short report. — Analyst downgrades typically trigger further institutional selling and lower price targets.
-0.40Which stocks this story touches
Continue reading
6 related stories
Top 3 movers · tap to explore
The company is facing a securities fraud class action lawsuit and allegations of channel stuffing following a significant stock price collapse.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
13h ago
